



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	117.75
Trade Time:	4:00 PM ET May 24, 2017
Change:	0.44 (0.375%)
Day Range	116.97 - 117.93
52-Week Range	94.42 - 127.64
Volume	2,692,040

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA® and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 22, 2017
[Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis](#)

May 17, 2017
[Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology \(ASCO\)](#)

May 6, 2017
[Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes](#)

May 3, 2017
[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)

Apr 27, 2017
[Celgene Reports First Quarter 2017 Operating and Financial Results](#)

Upcoming Events [\[View all \]](#)

May 31, 2017 4:00 PM ET
[Sanford C. Bernstein Strategic Decisions Conference](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 10, 2017
[Annual Report \(10-K\)](#)

Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)

Apr 27, 2017
[Quarterly Report \(10-Q\)](#)

Oct 27, 2016
[Quarterly Report \(10-Q\)](#)

Jul 28, 2016
[Quarterly Report \(10-Q\)](#)